Why Is Teva Stock Trading Higher On Tuesday?

Teva Pharmaceutical (TEVA) and Biolojic Design are advancing BD9, a dual-specific antibody targeting TSLP and IL-13, into IND-enabling studies for TH2-driven inflammatory diseases like atopic dermatitis and asthma; Biolojic will receive milestone payments tied to BD9's progress. This development follows FDA approval of Teva's interchangeable biosimilar Selarsdi and a settlement with Axsome Therapeutics regarding Auvelity patents, while the FDA issued a warning about anaphylaxis risk associated with Teva's glatiramer acetate; TEVA stock is up 6.01% at $17.98.

Analysis

Teva Pharmaceutical Industries Ltd (TEVA) is advancing its biopharmaceutical pipeline with the initiation of IND-enabling studies for BD9, a novel dual-specific multibody targeting both TSLP and IL-13, for TH2-driven inflammatory diseases such as atopic dermatitis and asthma. This progression, activating milestone payments to its partner Biolojic Design Ltd, underscores Teva's strategic pivot towards innovative biopharmaceuticals and holds potential for improved outcomes in patient populations with unmet needs. This development is complemented by other positive news, including the May U.S. FDA approval of Teva and Alvotech's (ALVO) Selarsdi, an interchangeable biosimilar to Johnson & Johnson's (JNJ) Stelara, and a February settlement with Axsome Therapeutics (AXSM) resolving patent litigation over Auvelity. These factors contribute to a strongly positive sentiment, evidenced by Teva's stock rising 6.01% to $17.98. However, a degree of caution is warranted due to a January FDA warning concerning the risk of anaphylaxis associated with glatiramer acetate (Copaxone), a key Teva product for multiple sclerosis, which could present a headwind despite the overall optimistic outlook derived from pipeline advancements and recent approvals.

Key Decisions for Investors

• Investors should closely monitor the progress of BD9 through IND-enabling studies and subsequent clinical trials, as successful development would significantly bolster Teva's biopharma portfolio and growth prospects.
• The commercial launch and market uptake of Selarsdi, particularly its interchangeability status with Stelara, should be evaluated for its revenue contribution and impact on Teva's biosimilar segment.
• Consider the potential financial impact of the FDA warning on glatiramer acetate sales and any further regulatory scrutiny, balancing this risk against the positive developments in Teva's pipeline and recent patent settlements.